Compounded Semaglutide After a Wegovy Denial: What Is Legal, What It Costs, and What to Do

Yes, you may still have a path after a denial—but the denial is not, by itself, a legal reason for a pharmacy to make routine compounded copies of Wegovy. Before you pay a telehealth company, find out what kind of denial you received. A missing prior authorization can often be fixed. A plan exclusion usually cannot. A cash-price Wegovy program may now cost less than a mid-priced compounded program. And a compounded prescription still needs its own lawful, patient-specific basis.

That is the part most pages skip.

A search for compounded semaglutide after a Wegovy denial usually starts with one fear: My insurance said no. Am I now stuck paying $1,000 or more every month? In 2026, the answer is often no. But the best next move depends on the denial letter, your medical reason for using semaglutide, your coverage, and whether you are comparing the real renewal price instead of the first-month ad.

Bottom line

• Missing paperwork or prior authorization: fix the file before you abandon coverage.
• Clinical-criteria denial: compare the denial wording with the exact FDA-labeled indication your prescriber is using.
• Plan exclusion: an appeal may not create a benefit your plan does not offer; compare current approved-drug cash prices and then discuss lawful alternatives.
• Compounded route: ask which pharmacy will fill it, what form of semaglutide it uses, what patient-specific reason or narrow copy-policy basis applies, and what you will pay after month one.

Choose Your Path in 30 Seconds

Need the fastest next step?

• Compare insurance-first GLP-1 paths
• Compare cash-pay options with Find My Path
• Use the Find My Path tool

Those are different decisions. Do not let a provider blend them into one button.

Quick Navigation

• Why was Wegovy denied?
• What should you do first?
• What does Wegovy cost after a denial?
• Can you still get compounded semaglutide?
• Is compounded semaglutide the same as Wegovy?
• Does insurance cover compounded semaglutide?
• Can a Wegovy appeal still work?
• Why does baseline BMI matter?
• What if you already started treatment?
• When is the compounded route worth discussing?
• How do you vet a provider and pharmacy?
• Frequently asked questions

Why Was Wegovy Denied?

A Wegovy denial is not one thing. It can mean the plan needs a form, the file missed a clinical rule, the plan wants another drug first, or the benefit does not exist. Those paths should not be handled the same way.

The denial letter matters more than the word denied.

1. The prior authorization was missing or incomplete

This is the most fixable type. The plan may need one or more of these:

• your BMI before you started any GLP-1 or GLP-1/GIP medicine;
• a qualifying weight-related condition;
• proof of a diet, activity, or behavioral program;
• dates and results from earlier treatment;
• a diagnosis code that matches the requested indication;
• a current office note;
• a statement that you will not use another GLP-1 drug at the same time;
• a prescriber answer that was left blank.

A one-page denial letter can hide a very small problem. Ask for the exact missing field. Do not settle for “insurance denied it.”

2. The plan says you did not meet its clinical criteria

This is different from missing paperwork. The plan may have the records and still say the request fails its rule.

For chronic weight management, a policy may require a baseline BMI of at least 30, or at least 27 with a qualifying condition. It may also require a documented treatment program or a minimum amount of weight loss for renewal. Those are plan rules, not a universal promise.

Wegovy also has FDA-labeled uses beyond chronic weight management. It is approved to reduce major cardiovascular events in certain adults with cardiovascular disease and overweight or obesity, and it has an adult indication for noncirrhotic MASH—metabolic dysfunction-associated steatohepatitis, a serious fatty-liver disease—with moderate-to-advanced liver fibrosis. Wegovy is not the semaglutide brand approved to treat type 2 diabetes. That is Ozempic. The right question is not “Does the plan cover semaglutide?” It is “Does the requested drug, diagnosis, and indication match?”

3. The plan requires step therapy or a preferred drug

Some plans want a different covered treatment first. That could be another anti-obesity medicine, a preferred GLP-1 product, or a documented reason the preferred option is not right for you.

Ask four concrete questions:

1. Which exact drug or step is required?
2. How long must it be tried?
3. What counts as failure, intolerance, or contraindication?
4. Is there an exception form?

A verbal answer from a call-center worker is useful, but the written policy is better. Ask the plan to send it.

4. Weight-loss drugs are excluded from the benefit

This is the hardest denial because the problem may not be your medical record. The employer or plan may have chosen not to cover anti-obesity drugs.

You can still ask whether Wegovy is covered under another FDA-labeled indication that you actually meet. But a prescriber cannot invent cardiovascular disease, MASH, or another diagnosis to get around a weight-loss exclusion.

A perfect prior authorization does not create a benefit that the plan document removes. That is the point where more paperwork can become wasted motion.

The original one-document promise does not hold up

You may see claims that the “three common denial types” are usually fixed by one document. We could not find a primary-source overturn rate that supports that promise. One missing note can fix an incomplete request. It cannot usually fix a plan exclusion, and it may not fix a clinical-criteria denial.

That is why this page uses four practical denial buckets instead of one appeal script for everyone.

What Should You Do First After a Wegovy Denial?

Get the denial reason in writing before you switch drugs, switch providers, or pay cash. The first 30 minutes can save you from a month of guessing.

Step 1: Get the full denial letter

Ask for:

• the denial code;
• the exact reason;
• the policy or coverage criteria used;
• the appeal deadline;
• whether the request was treated as a prior authorization, formulary exception, or excluded benefit;
• the mailing, fax, or online appeal route.

Take a picture or save the PDF. The exact words decide the next move.

Step 2: Call the prescriber’s office with one question

Say:

“My Wegovy request was denied for [read the exact reason]. What document or policy requirement is missing, and who is sending it?”

Do not ask only, “Can you appeal?” That can lead to another copy of the same failed request.

Step 3: Check the approved-drug cash price before you assume compounded is cheaper

NovoCare’s posted 2026 cash prices changed the comparison. Standard-dose Wegovy pens are listed at $349 per monthly fill through the direct self-pay program. Eligible new pen patients may pay $199 for each of the first two fills. Wegovy pill prices depend on the strength. Those prices can be lower than some compounded subscriptions once the first-month teaser ends.

The approved product may still be too expensive. But check the real number before you decide.

Step 4: Decide whether the denial is worth appealing

Appeal when:

• required information was missing;
• the plan used the wrong baseline BMI;
• the request used the wrong indication or left out a qualifying condition;
• the policy allows an exception;
• you completed the required step and the plan did not see it;
• the plan says a criterion was not met and your record shows that it was.

Move to a cash comparison sooner when:

• the plan document clearly excludes the benefit;
• the appeal deadline has passed and no exception applies;
• the cost of waiting is greater than the realistic chance of approval;
• the approved cash price is affordable enough to remove the coverage fight.

You can appeal and compare cash options at the same time. You do not have to wait in a dead zone.

What Does Wegovy Cost After an Insurance Denial?

The current approved-drug cash floor is no longer “list price or nothing.” As verified on August 25, 2026, NovoCare lists several direct self-pay prices. Eligibility, dose, timing, and program terms matter.

Current posted Wegovy cash prices

Commercially insured patients may also have access to a savings offer that can lower a fill to as little as $25, subject to eligibility and a maximum benefit. Federal and state health-program beneficiaries are excluded from that commercial savings card.

That is not the same as the direct self-pay program. NovoCare says a person with commercial or government-funded insurance may choose to self-pay through the direct program, but the purchase is not submitted as an insurance claim and generally does not count toward the deductible or out-of-pocket maximum.

Eligible Medicare patients also have a separate GLP-1 Bridge price of $50 per month for Wegovy pill or pen doses from July 1, 2026, through December 31, 2027, under the current program terms.

Current provider-stated compounded prices

These are posted program prices, not proof that the products are equal. A telehealth company may change the pharmacy, formulation, dose policy, state availability, or terms. Confirm everything before paying.

What the six-month math changes

The old “compounded costs about $299 and the gap is only $0 to $50” shortcut is no longer accurate.

At current posted rates:

• some long-commitment compounded programs are far below the approved cash price;
• some compounded programs are close to, or above, the current Wegovy pill or pen path;
• the first-month ad can hide a much higher refill price;
• a low monthly number can require six or 12 months of commitment;
• the cheapest row does not tell you which pharmacy will dispense, which ingredient form will be used, or whether the prescription fits the post-shortage rules.

This is why we show six-month cash outlay instead of sorting by the loudest first-month number.

Decision point

• Choose the approved cash lane when you want an FDA-approved product, the current price fits your budget, and you do not need the plan to count it toward your deductible.
• Keep working the insurance lane when the denial is fixable or the approved indication was documented incorrectly.
• Compare compounded programs only after you know the renewal price, commitment, pharmacy, ingredient form, and prescription basis.

Compare cash-pay options with Find My Path

Can You Still Get Compounded Semaglutide After a Wegovy Denial?

Sometimes, but not because insurance denied Wegovy. The broad shortage-based path for routine copies ended in 2025. Under Section 503A, a valid patient-specific prescription still must meet federal and state rules, including the restriction on making essentially identical copies regularly or in inordinate amounts. A prescriber-documented change that creates a significant difference for an identified patient is one narrow route. FDA also says it does not currently intend to act under that copy restriction when a compounder fills four or fewer prescriptions of that compounded product in a calendar month. That is enforcement discretion, not FDA approval or a broad telehealth exception.

A denial answers a payment question. Compounding law asks different questions.

We are not saying that to scold anyone. We are saying it because many pages quietly treat a denial as a legal green light. It is not one.

If you explore the compounded route, ask what patient-specific medical reason supports the prescription and which post-shortage copy rule the prescriber and pharmacy say applies. A documented significant difference is one answer. FDA’s four-or-fewer monthly enforcement threshold is another narrow answer. “Insurance denied it” is not an answer by itself.

The four-or-fewer point is easy to misread

FDA’s statement is an enforcement policy for one part of the “essentially a copy” restriction. It does not mean:

• four prescriptions make an unapproved drug FDA-approved;
• every telehealth company may sell four prescriptions to every patient;
• state pharmacy law disappears;
• a bulk, standardized copy program becomes lawful;
• the pharmacy may use any form of semaglutide;
• safety, labeling, valid-prescription, or quality rules stop applying.

A provider should be able to explain the actual pharmacy and legal basis without turning the answer into a sales pitch.

What about semaglutide plus B12?

B12 is often marketed as the difference. The label alone does not settle the question.

Ask:

1. Why does this patient need B12 in the same preparation?
2. What amount is added?
3. What significant difference does the prescriber expect for this identified patient?
4. Is the explanation documented in the prescription or medical record?
5. Is the provider relying on a significant-difference analysis, the four-or-fewer enforcement threshold, or another rule?

“Everyone gets B12” sounds like a standard product, not a patient-specific explanation.

Is Compounded Semaglutide the Same as Wegovy?

No. It may contain semaglutide, but it is not Wegovy and it is not reviewed by FDA as the same finished product. The difference is not just the logo on the box.

The Wegovy pen does not use a dial-a-dose system

The U.S. standard-dose Wegovy pen is a single-dose prefilled pen. The original draft described an adjustable dial. That was wrong for the U.S. standard-dose Wegovy pen.

That matters because a compounded vial may ask the patient to measure a volume with a syringe. The prescription may be written in milligrams, the vial may show milligrams per milliliter, and the syringe may show units. Those are three different scales.

FDA has reported compounded injectable semaglutide dosing errors involving five to 20 times the intended dose. Some patients needed hospital care. The errors included patient mistakes and prescriber calculation mistakes.

Do not use a social-media dose chart or a calculator made for another vial. Use the exact concentration on your label and the exact instructions from the prescriber and dispensing pharmacist.

FDA adverse-event reports are a warning signal, not a head count of proven injuries

As of May 31, 2026, FDA said it had received 990 reports associated with compounded semaglutide and more than 730 reports associated with compounded tirzepatide.

Those numbers do not prove that the compounded drug caused every event. Reports can be incomplete, duplicates can occur, and reporting differs across products. They also do not measure the rate per prescription because the number of compounded doses used is not known.

The numbers still matter. They are large enough that a buyer should not accept “it is exactly the same as Wegovy” as the full safety explanation.

What the MEDVi warning letter does—and does not—prove

FDA sent MEDVi a warning letter over marketing that could make unapproved compounded GLP-1 products look like they had the same active ingredient and benefits as approved drugs. MEDVi is a telehealth marketer, not the dispensing compounder.

That letter is relevant to advertising and product-status claims. It was not a recall, a contamination finding, or proof that every prescription filled through MEDVi harmed a patient. The fair takeaway is narrower: do not let “same active ingredient” language erase the fact that the finished compounded product is unapproved and pharmacy-specific.

Red flags that should stop the checkout

Do not continue until you get a clear answer when a program:

• will not name the dispensing pharmacy;
• cannot confirm the pharmacy is licensed to ship to your state;
• says the product is “FDA-approved compounded semaglutide”;
• says it is “the same as Wegovy” without explaining the difference;
• uses semaglutide sodium or acetate;
• gives a dose only in “units” without the vial concentration;
• refuses to explain the renewal price;
• promises a prescription before a clinician reviews you;
• will not explain who handles a dosing mistake or adverse event;
• treats an insurance denial as the medical reason for compounding.

Does Insurance Cover Compounded Semaglutide?

Most online compounded-semaglutide programs are built as cash-pay programs, but “insurance never covers it” is too broad. A plan may deny the drug, exclude compounded products, or refuse the telehealth bundle. A patient may also have an out-of-network or manual reimbursement path. You have to ask.

The practical issue is that many online programs do not submit a normal pharmacy claim. You pay the telehealth company or pharmacy, then the plan sees nothing unless you file paperwork yourself.

Ask the provider for:

• an itemized receipt;
• the prescriber’s name and NPI;
• the dispensing pharmacy’s name and NPI or NABP details;
• the prescription number;
• the drug name, quantity, and date;
• a diagnosis or letter of medical necessity when the plan requires it;
• the correct claim form.

Yucca’s current FAQ says it does not provide an itemized receipt or letter of medical necessity. That may make reimbursement harder even when a plan has an out-of-network process.

Can you use HSA or FSA money?

A prescribed medication can be a qualified medical expense under the tax rules, but a bundled telehealth charge can contain separate services. A card being accepted at checkout does not decide the tax result.

Before using HSA or FSA funds, ask for an itemized receipt that separates:

• clinician visit;
• membership or support fee;
• medication;
• shipping;
• labs;
• nonmedical add-ons.

Keep the prescription and receipt. Ask the plan administrator or tax professional when the charge is mixed or unclear. Do not rely on a provider’s “HSA/FSA accepted” badge as a tax ruling.

Government coverage and cash programs are not the same thing

The commercial Wegovy savings card excludes people enrolled in federal or state health programs. The direct NovoCare self-pay route is different: current terms allow a person with commercial or government-funded insurance to choose self-pay, but the transaction is not submitted to the plan and does not count toward normal cost-sharing totals.

Eligible Medicare patients should check the separate $50-per-month GLP-1 Bridge before paying a standard cash price.

Check the current NovoCare Medicare Bridge terms before paying the standard cash price.

Can a Wegovy Appeal Still Work?

Yes, when the denial is fixable. No appeal letter can guarantee approval, and no letter can create a benefit that the plan excludes.

Match the document to the denial

Use this call script

“Please read me the exact denial reason and the policy section used. Was this denied because information was missing, because I did not meet clinical criteria, because another drug is required first, or because the benefit is excluded? Please send me the full policy and tell me the appeal deadline.”

Then ask the prescriber:

“The plan says [exact wording]. Please compare that with the chart. Was my pre-treatment BMI included? Was the correct indication used? Was the required treatment history attached? What new document will be sent?”

Those questions create movement. “Please try again” often creates another denial.

Know the deadline

For Medicare Part D, you generally must ask for the first appeal within 65 calendar days of the date on the denial notice. After the plan receives that first-level drug appeal, the usual decision time is much shorter—generally seven days for a standard review or 72 hours for an expedited review.

For many employer health plans governed by federal claims rules, a claimant generally has at least 180 days after an adverse benefit determination to appeal.

Your letter controls. Some reviews move much faster, and urgent or expedited rules can apply. Read the notice instead of counting from memory.

Should you use an insurance-first telehealth service?

It can help when you need a clinician, prior-authorization support, and a coverage path in one place. It adds a service fee, and the medication cost is separate.

Ro currently lists:

• $39 for the first month;
• $149 month to month after that;
• an annual prepaid option that works out to as low as $74 per month.

Its public coverage checker requires an insurance card and is limited to certain pen products—Ozempic, Wegovy, and Zepbound pens. It is not a universal checker for Wegovy tablets, KwikPen products, Foundayo, or every GLP-1 product.

Sesame currently lists a $59-per-month annual membership for its weight-care program, with medication priced separately.

The service is worth paying for only when the work you need matches the service it actually performs.

Compare providers that work with insurance

Why Baseline BMI Can Decide the Appeal

A lower BMI after treatment can hurt a renewal or new request when the plan needs the BMI from before treatment. This is one of the easiest records to lose when a patient changes doctors, changes plans, or pays cash for the first months.

Cigna’s April 15, 2026 weight-loss GLP-1 policy is a useful example. It is not a promise for every Cigna member. The plan document controls.

For the policy’s standard adult weight-management path, the published criteria include:

• baseline BMI measured before any GLP-1 or GLP-1/GIP treatment;
• BMI of at least 30, or at least 27 with a listed weight-related condition;
• three months of behavioral modification and dietary restriction;
• an initial approval period of eight months;
• a continuation check that includes at least 5% weight loss from baseline;
• a one-year continuation approval period;
• no use with another GLP-1 drug.

The original finding was real: the baseline is the pre-treatment number, not simply today’s number.

The evidence packet to build now

Save one folder with:

1. earliest weight and height before any GLP-1 treatment;
2. date that weight was measured;
3. BMI calculation;
4. diagnoses that existed at that time;
5. medication history;
6. diet, activity, or behavioral-program records;
7. dates of each Wegovy or semaglutide fill;
8. current weight and percentage change;
9. side effects, missed doses, or treatment interruptions;
10. the current plan policy and denial letter.

That folder can matter even if you pay cash today and seek coverage later.

Baseline BMI calculator

Use the charted pre-treatment weight, not a guessed memory.

• BMI = weight in kilograms ÷ height in meters squared
• Pounds to kilograms: pounds ÷ 2.2046
• Inches to meters: inches × 0.0254

Do not change a charted number to fit a threshold. If the chart has an obvious data-entry error, ask the office to correct it with a dated note.

What If You Already Started Semaglutide?

Do not guess at a restart dose after a gap. The right plan depends on the product, dose, time missed, side effects, and your medical history.

The Wegovy prescribing information has missed-dose instructions and tells prescribers to consider reinitiating the dose-escalation schedule after multiple missed doses to reduce stomach and intestinal side effects. A compounded product may have a different concentration and different label directions.

Call the prescriber or dispensing pharmacist before you:

• restart after several missed doses;
• use an old vial;
• copy the dose from a different concentration;
• switch between pen, pill, and compounded vial;
• combine two GLP-1 products;
• double a dose;
• transfer a syringe-unit number from one pharmacy’s vial to another.

The original draft said stopping “cold” is not dangerous. That is too broad for a page that cannot see your medical history. The bigger common problem may be loss of treatment effect, return of appetite, higher glucose in a person using a diabetes medicine, or stronger side effects after an aggressive restart. But the page cannot promise that abrupt stopping is harmless for every reader.

What happens to weight after stopping?

Many people regain weight after stopping GLP-1 treatment. That does not mean you failed. It means the medicine was doing part of the work while you were taking it.

Ask for a continuity plan before the last dose:

• appeal timeline;
• approved cash fallback;
• refill timing;
• safe missed-dose instructions;
• food and activity plan;
• monitoring for glucose or other conditions;
• lower-cost approved alternatives;
• what to do if side effects or supply interrupt treatment.

A plan made before the gap is cheaper than panic after it.

Is the patient in legal trouble for receiving a compounded prescription?

This page cannot give a blanket legal guarantee. The main federal rules discussed here regulate compounding, dispensing, marketing, and professional conduct. State law and the facts still matter. Do not let a sales page tell you “nobody can come after you” as if it reviewed your situation.

The useful question is simpler: Is the prescriber and pharmacy giving you a clear, documented, lawful path—or asking you not to look too closely?

When Is Compounded Semaglutide Worth Discussing?

Compounded semaglutide may be worth discussing when an approved option does not meet a patient’s medical need, when a prescriber can document a patient-specific significant difference, or when all 503A requirements are met and a pharmacy’s limited dispensing falls within FDA’s current four-or-fewer enforcement policy. Affordability can drive the question. It does not, by itself, supply the compounding basis.

Here are the situations where the discussion becomes most useful.

Situation 1: Your plan excludes weight-loss drugs

The exclusion may leave you with no covered weight-management drug. Lower compounded prices can make you want to explore that lane.

The right question is not “Does the denial qualify me?” It is:

“What medical reason supports my prescription, and which post-shortage compounding rule do the prescriber and pharmacy say it meets?”

Also compare the current approved-drug cash price. A $349 Wegovy pen or dose-based Wegovy pill path may be more attractive than a $299 compounded renewal once product status and device convenience are included. A $69 or $73 long-term compounded offer may still be far cheaper, but the commitment and pharmacy questions become more important, not less.

Situation 2: A patient needs a documented change that the approved product cannot provide

A prescriber may identify a change that makes a significant difference for that patient. The reason should be real and documented.

Examples can include a needed dosage form or ingredient change, but the facts must come from the clinician. “Cheaper” and “insurance denied it” do not describe a medical difference.

Situation 3: You are between coverage paths

A person may be waiting for an appeal, employer-plan change, or new coverage. A clinician can discuss available treatment choices and continuity.

Do not assume a short bridge is automatically lawful compounding. Ask the same pharmacy, ingredient, prescription, and copy-rule questions.

Situation 4: The approved cash program is still unaffordable

This is the hardest reality. A lawful and carefully vetted compounded option may be the only price a person can pay. That does not make the product FDA-approved. It does make transparent comparison more important.

Look for:

• exact refill price;
• no hidden dose-increase charge;
• named pharmacy;
• state license;
• ingredient form;
• concentration;
• clear dosing support;
• refund terms;
• documented medical and legal basis;
• a real plan for adverse events and continuity.

When the compounded route is a poor fit

It may be a poor fit when:

• you need the certainty of an FDA-approved finished product;
• you cannot get the pharmacy name before paying;
• the provider uses a salt form;
• the provider will not explain the concentration;
• you are likely to confuse syringe units;
• you want the purchase to count toward an insurance deductible;
• you cannot accept a prepaid commitment;
• the approved cash price fits your budget;
• your denial is likely fixable with one missing record;
• the provider’s only legal explanation is “the shortage” or “your insurance denied it.”

How to Vet a Compounded Semaglutide Provider

Vet the prescriber, the telehealth company, and the dispensing pharmacy as three separate parties. A clean website is not a pharmacy license.

Ask these questions before payment:

1. What is the full name and physical address of the dispensing pharmacy?
2. Is that pharmacy licensed to ship to my state?
3. Is it a traditional 503A pharmacy or a registered 503B outsourcing facility?
4. What patient-specific medical reason supports this prescription, and what copy-rule basis applies? If the prescriber relies on a significant difference, ask what change will be documented. If the pharmacy relies on FDA’s four-or-fewer enforcement policy, ask whether this exact compounded product stays within that monthly threshold.
5. Is the ingredient semaglutide base—not semaglutide sodium or acetate?
6. What will the vial concentration be in mg/mL?
7. What is my dose in milligrams, and what syringe marking matches that dose for this exact vial?
8. Does the price rise with dose?
9. What is the full renewal price, commitment, cancellation deadline, and refund rule?
10. Who answers after-hours dosing questions or adverse-event calls?
11. Can I get an itemized receipt and prescription record?
12. What happens if the pharmacy, formulation, law, or availability changes next month?

Verify the pharmacy yourself

Use the state board of pharmacy where the pharmacy is located and the board for your own state when required. Confirm:

• active license;
• legal business name;
• address;
• disciplinary history;
• nonresident pharmacy authority;
• pharmacist-in-charge;
• whether the license type matches the service described.

A telehealth company’s own “licensed pharmacy” badge is not independent verification.

Ask for the label before the first injection

The label should let you identify:

• patient;
• pharmacy;
• prescriber;
• ingredient;
• concentration;
• beyond-use date;
• storage;
• lot or prescription details;
• dose instructions;
• contact number.

Call the pharmacy when the written dose and syringe markings do not make immediate sense. Confusion is a reason to stop, not a reason to guess.

Provider-Stated Claims vs. What You Can Verify Before Paying

This table is intentionally blunt. A provider can state a price or policy on its own page. That does not independently prove what a specific patient will receive.

The damaging admission

We can verify posted prices. We can verify public policies. We can verify FDA actions. We can verify a pharmacy license after we know the pharmacy name.

We cannot verify the exact vial you will receive before the provider and pharmacy create it. We cannot tell you that a $69 program is safer than a $299 program because the monthly price does not prove sterility, potency, or clinical quality. We cannot tell you that every low-price program will keep that price. And we cannot turn a provider’s “same active ingredient” sentence into FDA approval.

A page that pretends otherwise may convert better for one day. It does not help you make the right decision.

Which Path Is Best After a Wegovy Denial?

Use the denial, not the fear, to choose.

Choose the appeal path when:

• information was missing;
• the plan used the wrong baseline;
• you meet the written criteria;
• a required step is already complete;
• an exception is available;
• the wrong indication was submitted.

Next step: Compare insurance-first providers

Choose the approved cash path when:

• the current NovoCare price fits;
• you want an FDA-approved product;
• you prefer a prefilled pen or approved pill;
• you do not need the transaction to count toward insurance cost sharing;
• waiting for an appeal would create a treatment gap.

Next step: Check the current NovoCare terms first. That is a drug-price check, not an affiliate recommendation.

Discuss the compounded path when:

• the approved product does not meet a patient-specific need;
• a prescriber can explain and document the basis;
• the pharmacy is named and licensed;
• the ingredient form is clear;
• the concentration and dose instructions are clear;
• the renewal price and commitment fit;
• you accept that the product is not FDA-approved.

Next step: Compare cash-pay options with Find My Path

Use the decision tool when you are still stuck

The tool asks about insurance, diagnosis, cash budget, format, and whether you want an approved or compounded path.

Next step: Find My GLP-1 Path

Frequently Asked Questions

Can I get compounded semaglutide because Wegovy was denied?

Sometimes, but the denial itself does not qualify you. The broad shortage-copy path ended. A 503A patient-specific prescription still has to meet the valid-prescription and copy restrictions. A documented significant difference is one narrow route. FDA also says it does not currently intend to act under the regular-or-inordinate copy restriction when a compounder fills four or fewer prescriptions of that compounded product in a calendar month. Every other 503A and state-law condition still applies.

Ask:

“What medical reason supports my prescription, and which post-shortage compounding rule are the prescriber and pharmacy relying on?”

Is compounded semaglutide FDA-approved?

No. Compounded drugs are not FDA-approved. FDA does not review each compounded finished product for safety, effectiveness, or quality before it reaches a patient.

Is compounded semaglutide the same as Wegovy?

No. Wegovy is an FDA-approved finished product with approved labeling and delivery systems. A compounded product may contain semaglutide, but the pharmacy, concentration, ingredient source, container, instructions, testing, and oversight can differ.

Is compounded semaglutide cheaper than Wegovy?

Sometimes. Current posted compounded programs range from about $69 per month on a 12-month plan to $299 for MEDVi refill months in the programs checked for this page. Current NovoCare prices include $349 for standard-dose Wegovy pens, dose-based pill prices from $149 to $299, and a $199 first-two-fill offer for eligible new pen patients. Compare six months, not month one.

What is the cheapest current option in the table?

Embody posts $69 per month on a 12-month plan and $73 per month on a six-month plan. That is a provider-stated program price, not a quality ranking or a promise that every patient is eligible. Read the commitment, cancellation, pharmacy, and formulation terms.

Does the Wegovy savings card work with Medicare or Medicaid?

The commercial savings card excludes federal and state health-program beneficiaries. A separate direct self-pay route may still be used by a person with government-funded insurance without submitting the claim. Eligible Medicare patients should also check the temporary $50-per-month GLP-1 Bridge program.

Will a cash Wegovy purchase count toward my deductible?

NovoCare’s direct self-pay terms say the purchase is not submitted to insurance. It generally will not count toward the deductible or out-of-pocket maximum. Confirm with the plan if you have a separate reimbursement process.

Does insurance cover compounded semaglutide?

Sometimes a plan may have a manual or out-of-network path, but many online programs are cash pay and do not submit a normal pharmacy claim. Ask the plan and request an itemized receipt before assuming reimbursement.

Can I use HSA or FSA money?

A prescribed medication may qualify, but a bundled membership can include services with different treatment under the tax rules. Keep an itemized receipt and prescription. Card acceptance alone is not a tax decision.

What should I send with a Wegovy appeal?

Send what answers the denial: the full policy, pre-treatment BMI, qualifying conditions, treatment history, required program records, step-therapy proof, and a label-based medical rationale. Do not send a generic letter when the plan named a specific missing fact.

What if my BMI is lower now because semaglutide worked?

Ask the clinician to document the baseline BMI from before treatment and the percentage lost from that baseline. Some policies, including the Cigna policy reviewed for this page, define baseline before any GLP-1 or GLP-1/GIP treatment.

Can I restart at my old dose after a gap?

Do not assume so. Ask the prescriber or pharmacist. The approved Wegovy instructions allow the clinician to consider reinitiating dose escalation after multiple missed doses. A compounded vial can have a different concentration.

Does adding B12 make compounded semaglutide legal?

Not automatically. FDA has explained that semaglutide plus B12 may still be treated as essentially a copy when the route is the same and the ingredient amounts are within 10% of commercially available strengths. A patient-specific significant difference must be documented when that is the route relied on. FDA’s separate four-or-fewer enforcement threshold is not product approval.

Are compounded semaglutide adverse events common?

FDA has report counts, not a clean rate. As of May 31, 2026, it reported 990 adverse-event reports associated with compounded semaglutide. The reports do not prove causation and cannot be divided by a known number of users to produce a reliable rate.

What form of semaglutide should a compounder use?

Ask whether it uses semaglutide base. FDA has warned that semaglutide sodium and semaglutide acetate are different active ingredients from the one used in approved semaglutide drugs.

Is MEDVi unsafe because it received an FDA warning letter?

The warning letter addressed marketing and unapproved-product claims. It was not a recall or a finding that every dispensed product was contaminated. It is still a reason to read product-status language carefully and identify the actual dispensing pharmacy.

How often should this page be rechecked?

Prices, program terms, FDA policies, and plan criteria can change quickly. This page was last fully verified on August 25, 2026. Check the provider, payer, and FDA source again before paying or filing.

Sources and Verification Notes

Primary sources were used for prices, product status, federal compounding policy, dosing alerts, appeal timing, and the Cigna example.

1. Wegovy Prescribing Information
2. NovoCare — Wegovy direct self-pay, savings, and Medicare Bridge terms checked August 25, 2026
3. FDA: Compounding When Drugs Are on FDA’s Drug Shortages List
4. FDA: Concerns With Unapproved GLP-1 Drugs Used for Weight Loss
5. FDA: Dosing Errors Associated With Compounded Injectable Semaglutide
6. FDA Human Drug Compounding
7. Cigna Coverage Policy CNF684, “Weight Loss – Glucagon-Like Peptide-1 Agonists,” selected revision April 15, 2026; the member’s plan document controls
8. Medicare Appeals
9. U.S. Department of Labor: Claims Procedure Regulation FAQs
10. IRS Publication 969
11. Official provider pricing, FAQ, cancellation, and refund pages for Embody, Yucca, Enhance.MD, MEDVi, Ro, and Sesame, checked August 25, 2026

Editorial and Affiliate Disclosure

Weight Loss Provider Guide may earn a commission from some provider links. That does not change your price. It also does not turn provider-stated claims into independent proof.

The approved-drug cash check is placed before affiliate comparisons because a reader should see the nonaffiliate manufacturer option before choosing a compounded subscription.

This page does not diagnose, prescribe, calculate a dose, or replace a clinician or pharmacist. Compounding and pharmacy rules can vary by state and can change. For urgent symptoms, severe vomiting, inability to keep fluids down, severe stomach pain, fainting, trouble breathing, swelling, confusion, or a suspected overdose, seek urgent medical help or call Poison Control in the United States at 1-800-222-1222.